Project Grant R01CA293092
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$514K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop a novel cancer immunotherapy strategy using genetically engineered B cells. The research aims to exploit homology-driven gene editing to generate tumor-specific B cells that can directly kill cancer cells and trigger robust anti-tumor T cell immunity. The project will evaluate the efficacy and tolerability of this B cell-based...
This $604,627 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Trustees of Dartmouth College aims to deconvolve the heterogeneity of chimeric antigen receptor (CAR) T cells to engineer durable antitumor immunity. The research will use dynamic lineage recording to analyze individual CAR T cell differentiation trajectories, determine the requirements for host and CAR T cell memory, and identify the effects of tumor burden and immune checkpoint...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of The City of Hope to develop an innovative approach to enhance the efficacy and durability of CD19-targeted CAR T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The key elements of the project involve:
Selecting and modifying CMV-specific T cells with a CD19-targeting CAR, then infusing the bi-specific CMV-CD19 CAR T cells into...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $297,728 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing the antitumor activity of CD70 chimeric antigen receptor (CAR) T cells through targeted delivery of a VEGF-blocking single-chain variable fragment (scFv) in renal cell carcinoma. The key objectives are to determine the effect of locally secreted VEGF blockade on CD70...
This $195,766 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Yale University aims to develop a novel "mechano-transduction" platform to enhance the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The project will use force sensors to measure forces along key immune receptors, and engineer force transduction modules that combine these sensors with transcription activators to...
This federal Project Grant award, titled "Expanding CAR T Cell Applications Through High-Throughput Forward- and Reverse Immune Engineering," is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $1,525,500 award to New York University School of Medicine, spanning from September 1, 2024 to August 31, 2027, supports the development of new technologies to address key bottlenecks in the chimeric antigen receptor (CAR) T...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Sloan-Kettering Institute for Cancer Research to advance the development and translation of novel chimeric antigen receptor (CAR) T-cell therapies for solid tumors.
The key products or services to be delivered under this $1,313,806 award include:
Preclinical and clinical studies of CD28 costimulated CAR T-cells targeting the mesothelin antigen, with a focus on...
This $1,271,780 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop small molecule adaptors for reprogramming universal chimeric antigen receptor (CAR) T cells. The primary objectives are to: 1) create small molecule adaptors to target universal CAR T cells to multiple antigens, including tumor cells and immunosuppressive cells; 2) enhance CAR targeting specificity using chemical switches...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $652,725 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of a novel cellular immunotherapy called CARV3.TEAM-E cells for the treatment of glioblastoma, a deadly brain cancer. The CARV3.TEAM-E cells are engineered CAR-T cells that secrete a T cell-engaging antibody molecule to more effectively target tumor...
This $530,015 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the Fred Hutchinson Cancer Center in Seattle, Washington to investigate the immunomodulatory effects of natural killer (NK) cells on anti-tumor immune responses. The overarching goal is to define the cellular and molecular mechanisms regulating NK cell phenotype and function in the tumor microenvironment, with a specific focus on understanding how...